Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EG1206A (pertuzumab biosimilar) in HER2-positive early breast cancer
NCT06884254Phase 3Withdrawn
- Sponsor
- EirGenix
- Start
- May 2025
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pertuzumab in breast cancer (2 arms), sponsored by EirGenix. Primary endpoint: Pathologic Complete Response. Planned start May 2025; status: withdrawn.
02
Drugs
pertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06884254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06884254.